1NguyenDT,AmessJA,Dougkty H,et al.IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorder:evaluation of response on 48 patients[J].Eur J Haematol,1999,62(2):76:. 被引量：1
2WitzigTE,GordonLI,CabanillasF,et al.Randomized controlled trial of ytthrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for panents with relapsed or refractory low-grade,follicular,or transformed B-cell non-Hodgkin's lymphoma[J].J Clin Oncol,2002,20(10):2453. 被引量：1
3PegramMD,LopezA,KonecnyG,et al.Trastuzumab and chemotherapeutic drug interactions and synergies[J].Semin Oncol,2000,27(6Suppl 11):21. 被引量：1
4Mendelsohn J.Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy[J].Clin Cancer Res,1997,3(12 pt2):2703. 被引量：1
5Prewett M,HooperA,Bassi R,et al.Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-C225 in comdination with 5-fluorouracil or irinotecan[C].Proc Am Assoc Cancer Res,2001,42:287. 被引量：1
6Matsuno F,Haruta Y,Kondo M,et al.Induction of Lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies[J].Clin Cancer Res,1999,5(2):371. 被引量：1
8Yang XD,Jia XC,cORALAN JR,et al.Eradication of estabished tumors by a fully human monoclonal antibody to the epidemal growth factor receptor without concomitant chemotherapy[J].Cancer Res,1999,59(6):1236. 被引量：1
